Search

Your search keyword '"Syeda H. Afroze"' showing total 7 results
Start Over Author "Syeda H. Afroze" Publisher elsevier bv
7 results on '"Syeda H. Afroze"'

1. Reduced urinary angiotensinogen excretion in preeclampsia

Author

Thomas J. Kuehl, Syeda H. Afroze, Roksana Akter, A.H.M. Zuberi Ashraf, Ahmed F. Pantho, Mohammad N. Uddin, and Natalie S. Colόn

Subjects
Adult, medicine.medical_specialty, Urinary system, Rat model, Angiotensinogen, Enzyme-Linked Immunosorbent Assay, Preeclampsia, Excretion, chemistry.chemical_compound, Urinary excretion, Pre-Eclampsia, Pregnancy, Internal medicine, Internal Medicine, Animals, Humans, Medicine, reproductive and urinary physiology, Creatinine, business.industry, Obstetrics and Gynecology, medicine.disease, Angiotensin II, female genital diseases and pregnancy complications, Rats, Endocrinology, ROC Curve, chemistry, Case-Control Studies, embryonic structures, Female, Plasma angiotensin ii, business, Biomarkers
Abstract

OBJECTIVE This study evaluated urinary angiotensinogen in preeclampsia. METHODS Normal pregnant (n = 57) and preeclamptic patients (n = 31); Normal pregnant (n = 10) and preeclamptic rats (n = 10) were studied. Urinary angiotensinogen and plasma angiotensin II were assayed by enzyme-linked immunosorbent assay (ELISA). RESULTS Urinary angiotensinogen in preeclampsia patients (2.0 ± 1.1 ng/mg creatinine) was suppressed (*p

Published
2022

2. 818: A single-chain derivative of the relaxin hormone (b7-33) protects cytotrophoblasts from hyperglycemia-induced preeclampsia phenotype and induces the survival pathway

Author

David C. Zawieja, Nathan Drever, Mohammed Akhter Hossain, Thomas J. Kuehl, Syeda H. Afroze, Mohammad Nasir Uddin, and Ahmed F. Pantho

Subjects
Relaxin, medicine.medical_specialty, Obstetrics and Gynecology, Single chain, Biology, medicine.disease, Phenotype, Preeclampsia, chemistry.chemical_compound, Endocrinology, chemistry, Internal medicine, medicine, Cytotrophoblasts, Derivative (chemistry), Hormone
Published
2017

3. 879: Pravastatin protects cytotrophoblasts from a hyperglycemia-induced preeclampsia phenotype

Author

Katy B. Wesley, Maged M. Costantine, Richard O. Jones, Anthony R. Lewis, Steven R. Allen, Mohammad Nasir Uddin, Syeda H. Afroze, Nathan Drever, and Thomas J. Kuehl

Subjects
medicine.medical_specialty, Endocrinology, business.industry, Internal medicine, medicine, Obstetrics and Gynecology, Cytotrophoblasts, business, medicine.disease, Phenotype, Pravastatin, medicine.drug, Preeclampsia
Published
2017

4. Sa1700 Inhibition of the Substance P/Neurokinin 1 Receptor Signaling Axis Reduces Cholangiocarcinoma Growth In Vivo

Author

Matthew McMillin, Syeda H. Afroze, Gabriel Frampton, Holly Standeford, Fanyin Meng, Kelly McDaniel, Shannon Glaser, Sharon DeMorrow, Yuyan Han, Julie Venter, Laura Hargrove, Heather Francis, Micheleine Guerrier, Shanika Avila, and Gianfranco Alpini

Subjects
Liver injury, medicine.medical_specialty, Hepatology, Chemistry, Gastroenterology, Cholangiocyte proliferation, Substance P, medicine.disease, Cholangiocyte, chemistry.chemical_compound, Endocrinology, In vivo, Internal medicine, Tachykinin receptor 1, medicine, Phosphorylation, Galanin
Abstract

A S L D A b st ra ct s increase in circulating Galanin in the serum. Galanin immunoreactivity was observed in both cholangiocytes and hepatocytes, whereas GalR1 was found predominantly in cholangiocytes. Systemic treatment of rats with M617 increased both CK-19 expression and IBDM in both sham and BDL-treated animals. In vitro, treatment of the mouse cholangiocyte cell line with M617 increased ERK1/2 and RSK-1 activity. There was a concomitant increase in cholangiocyte proliferation after M617 treatment that could be blocked by pretreatment with inhibitors for ERK1/2 and RSK-1. Conclusions: Data presented here demonstrate a direct stimulatory role for Galanin on cholangiocyte proliferation under physiological (sham) and pathological (BDL) conditions via a mechanism involving the activation of ERK1/2 and subsequent phosphorylation of RSK-1. Targeting Galanin or GalR1 may prove a useful strategy to regulate biliary mass during cholestatic liver injury.

Published
2014

5. Sa1698 Downregulation of Menin by Mir-24-1 Increases Cholangiocarcinoma Proliferation

Author

Shannon Glaser, Terry C. Lairmore, Gergely Maté, Micheleine Guerrier, Fanyin Meng, Shanika Avila, Holly Standeford, Syeda H. Afroze, Gianfranco Alpini, Julie Venter, and Hassan Ammarzahid

Subjects
Liver injury, medicine.medical_specialty, Hepatology, Chemistry, Gastroenterology, Cholangiocyte proliferation, medicine.disease, In vitro, Cholangiocyte, Endocrinology, Downregulation and upregulation, Cell culture, Internal medicine, medicine, Phosphorylation, Galanin
Abstract

A S L D A b st ra ct s increase in circulating Galanin in the serum. Galanin immunoreactivity was observed in both cholangiocytes and hepatocytes, whereas GalR1 was found predominantly in cholangiocytes. Systemic treatment of rats with M617 increased both CK-19 expression and IBDM in both sham and BDL-treated animals. In vitro, treatment of the mouse cholangiocyte cell line with M617 increased ERK1/2 and RSK-1 activity. There was a concomitant increase in cholangiocyte proliferation after M617 treatment that could be blocked by pretreatment with inhibitors for ERK1/2 and RSK-1. Conclusions: Data presented here demonstrate a direct stimulatory role for Galanin on cholangiocyte proliferation under physiological (sham) and pathological (BDL) conditions via a mechanism involving the activation of ERK1/2 and subsequent phosphorylation of RSK-1. Targeting Galanin or GalR1 may prove a useful strategy to regulate biliary mass during cholestatic liver injury.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results